Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Beyond Deterministic Models in Drug Discovery and Development.
Irurzun-Arana I, Rackauckas C, McDonald TO, Trocóniz IF. Irurzun-Arana I, et al. Among authors: mcdonald to. Trends Pharmacol Sci. 2020 Nov;41(11):882-895. doi: 10.1016/j.tips.2020.09.005. Epub 2020 Oct 5. Trends Pharmacol Sci. 2020. PMID: 33032836 Free PMC article. Review.
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer.
Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K. Ge JY, et al. Among authors: mcdonald to. Nat Commun. 2020 May 11;11(1):2350. doi: 10.1038/s41467-020-16170-3. Nat Commun. 2020. PMID: 32393766 Free PMC article.
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer.
Cheng YC, Stein S, Nardone A, Liu W, Ma W, Cohen G, Guarducci C, McDonald TO, Jeselsohn R, Michor F. Cheng YC, et al. Among authors: mcdonald to. Cancer Res Commun. 2023 Nov 16;3(11):2331-2344. doi: 10.1158/2767-9764.CRC-23-0257. Cancer Res Commun. 2023. PMID: 37921419 Free PMC article.
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
Poels KE, Schoenfeld AJ, Makhnin A, Tobi Y, Wang Y, Frisco-Cabanos H, Chakrabarti S, Shi M, Napoli C, McDonald TO, Tan W, Hata A, Weinrich SL, Yu HA, Michor F. Poels KE, et al. Among authors: mcdonald to. Nat Commun. 2021 Jun 17;12(1):3697. doi: 10.1038/s41467-021-23912-4. Nat Commun. 2021. PMID: 34140482 Free PMC article. Clinical Trial.
109 results